ArticleVaccine2007
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 67 citations in OpenAlex.
- Foot-and-mouth disease vaccine with insertion of a 24-amino acid VP1 G-H loop epitope of the Cathay virus provides broad antigenic coverage.Applied microbiology and biotechnology · 2025Article
- Expression and Immunogenicity of Recombinant African Swine Fever Virus Proteins Using the Semliki Forest Virus.Frontiers in veterinary science · 2022Article
- Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA.Molecular therapy. Nucleic acids · 2021Article
- Article
- AnScience translational medicine · 2020Article
- Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.Journal of pharmaceutical analysis · 2020Review
- Next-generation influenza vaccines: opportunities and challenges.Nature reviews. Drug discovery · 2020Review
- Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.Vaccine · 2019Article
- Article
- The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.Antiviral research · 2015Review
- The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Cellular & molecular immunology · 2015Review
- Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.Journal of virology · 2014Article
- Fast vaccine design and development based on correlates of protection (COPs).Human vaccines & immunotherapeutics · 2014Review
- Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.PLoS pathogens · 2013Article
- Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.Cancer immunology, immunotherapy : CII · 2012Article
- Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.Clinical and vaccine immunology : CVI · 2012Article
- Article
- Progress in respiratory virus vaccine development.Seminars in respiratory and critical care medicine · 2011Review
- Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.Vaccine · 2011Article
- Vaccines for gonorrhea: can we rise to the challenge?Frontiers in microbiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-gamma ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.